Translate AMICOR contents if you like

Thursday, January 23, 2014


Artigo apontado pela Dra. Laura Barcellos.

Phase 3 Trials of Solanezumab for Mild-to-Moderate AD

Rachelle S. Doody, M.D., Ph.D., Ronald G. Thomas, Ph.D., Martin Farlow, M.D., Takeshi Iwatsubo, M.D., Ph.D., Bruno Vellas, M.D., Steven Joffe, M.D., M.P.H., Karl Kieburtz, M.D., M.P.H., Rema Raman, Ph.D., Xiaoying Sun, M.S., Paul S. Aisen, M.D., Eric Siemers, M.D., Hong Liu-Seifert, Ph.D., and Richard Mohs, Ph.D. for the Alzheimer's Disease Cooperative Study Steering Committee and the Solanezumab Study Group
N Engl J Med 2014; 370:311-321January 23, 2014DOI: 10.1056/NEJMoa1312889


Solanezumab, a humanized monoclonal antibody that binds amyloid, failed to improve cognition or functional ability. (Funded by Eli Lilly; EXPEDITION 1 and 2 numbers, NCT00905372 andNCT00904683.)/.../

No comments: